(Reuters) -Metsera, an obesity drug developer, said on Friday that it has entered into an amended merger agreement with Pfizer, in which the New York-based company will acquire Metsera for up to $86.25 per share. Metsera's board has recommended that its shareholders "approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer." (Reporting by Rishabh Jaiswal in Bengaluru; Editing by Leslie Adler and Thomas Derpinghaus)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Byron Kaye SYDNEY, Oct 6 (Reuters) - OpenAI and Anthropic told Australian parliament on…
* Anthropic doesn't believe its products have breached Australian government systems * Both Anthropic and…
By Rae Wee SINGAPORE, Oct 6 (Reuters) - The euro languished near a 17-month low…
Oct 6 (Reuters) - DeepSeek is close to securing at least 80 billion yuan ($11.93…
WARSAW, Oct 6 - The following are significant news stories, press reports and events on…
(Adds strategic stance of Sabadell in paragraph 4, details on BPCE seeking a board member…